Related Experiment Video
Updated: Feb 9, 2026
11:53
Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers
Published on: July 21, 2017
7.7K
3D-Printed Network Structures as Controlled-Release Drug Delivery Systems: Dose Adjustment, API Release Analysis and
Carolin Korte1, Julian Quodbach2
1Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstr. 1, 40225, Düsseldorf, Germany.
AAPS Pharmscitech
|June 2, 2018
Summary
3D printing enables customized sustained release drug delivery systems. This study developed 3D printed dosage forms with adjustable doses and predictable drug release profiles, paving the way for pharmacy-based personalized medicine.
Area of Science:
- Pharmaceutical Technology
- Materials Science
- Drug Delivery
Background:
- 3D printing offers potential for personalized drug therapy.
- Sustained release dosage forms require in vivo drug release estimation, often unavailable in pharmacies.
- Current limitations necessitate development of adaptable drug delivery systems.
Purpose of the Study:
- To develop a 3D printed sustained release drug delivery system.
- To enable dose adaptation and drug release estimation simultaneously.
- To explore the potential for customized dosage form production in pharmacies.
Main Methods:
- Hot-melt extrusion to create filaments (Eudragit® RL, theophylline, stearic acid).
- 3D printing of network structures with varying densities.
- X-ray microcomputed tomography for surface area and weight analysis.
- Dissolution studies to assess drug release kinetics.
Main Results:
- A linear correlation was observed between fill density, weight (dose), and surface area.
- Specific surface area remained consistent across different densities.
- Denser networks exhibited slower theophylline release.
- Linear interpolation provided good prediction of drug release (RMSEP 1.4-3.7%).
Conclusions:
- 3D printing allows for the creation of customized sustained release dosage forms.
- The developed system facilitates dose adjustment and drug release prediction.
- This technology holds promise for future pharmaceutical applications in hospital and community pharmacies.
Keywords:
3D printingadvanced drug delivery systemdissolution analysis and predictionextended release matrixpersonalized medicineMore Related Videos
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
230
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
230
01:28Energy-releasing Steps of Glycolysis
147.1K
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase.
The first energy-releasing step—the 6th step of glycolysis...
The first energy-releasing step—the 6th step of glycolysis...
147.1K
01:11Renal Failure: Dose Adjustments
487
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
487
01:10In Vitro Drug Release Testing: Overview, Development and Validation
363
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
363
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
922
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
922